BioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced its participation in two major upcoming investor conferences in March 2025. The company will present at the TD Cowen 45th Annual Health Care Conference in Boston on March 5 at 9:10 a.m. ET, and at the Barclays 27th Annual Global Healthcare Conference in Miami on March 11 at 10:00 a.m. ET.
Investors and interested parties can access live audio webcasts and replay recordings of both presentations through the Investors & Media section of BioCryst's website at biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha annunciato la sua partecipazione a due importanti conferenze per investitori che si terranno a marzo 2025. L'azienda presenterà alla TD Cowen 45ª Conferenza Annuale sulla Salute a Boston il 5 marzo alle 9:10 a.m. ET, e alla Barclays 27ª Conferenza Annuale Globale sulla Salute a Miami l'11 marzo alle 10:00 a.m. ET.
Gli investitori e le parti interessate possono accedere alle webcasts audio in diretta e alle registrazioni delle presentazioni attraverso la sezione Investitori & Media del sito web di BioCryst all'indirizzo biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha anunciado su participación en dos importantes conferencias para inversores que tendrán lugar en marzo de 2025. La compañía presentará en la TD Cowen 45ª Conferencia Anual de Salud en Boston el 5 de marzo a las 9:10 a.m. ET, y en la Barclays 27ª Conferencia Anual Global de Salud en Miami el 11 de marzo a las 10:00 a.m. ET.
Los inversores y partes interesadas pueden acceder a las transmisiones web en vivo y a las grabaciones de ambas presentaciones a través de la sección de Inversores y Medios del sitio web de BioCryst en biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX)는 2025년 3월에 열리는 두 개의 주요 투자자 컨퍼런스에 참여할 것이라고 발표했습니다. 이 회사는 3월 5일 오전 9시 10분 ET에 보스턴에서 열리는 TD Cowen 제45회 연례 건강 관리 컨퍼런스와 3월 11일 오전 10시 ET에 마이애미에서 열리는 Barclays 제27회 연례 글로벌 헬스케어 컨퍼런스에서 발표할 예정입니다.
투자자 및 관심 있는 분들은 BioCryst 웹사이트의 투자자 및 미디어 섹션을 통해 두 발표의 실시간 오디오 웹캐스트 및 재생 녹음을 접속할 수 있습니다. biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) a annoncé sa participation à deux grandes conférences pour investisseurs prévues en mars 2025. La société présentera lors de la 45e Conférence Annuelle sur la Santé TD Cowen à Boston le 5 mars à 9h10 ET, et lors de la 27e Conférence Annuelle Mondiale sur la Santé Barclays à Miami le 11 mars à 10h00 ET.
Les investisseurs et les parties intéressées peuvent accéder aux webdiffusions audio en direct et aux enregistrements des deux présentations via la section Investisseurs & Médias du site Web de BioCryst à l'adresse biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) hat seine Teilnahme an zwei wichtigen bevorstehenden Investorenkonferenzen im März 2025 bekannt gegeben. Das Unternehmen wird am 5. März um 9:10 Uhr ET auf der TD Cowen 45. jährlichen Gesundheitskonferenz in Boston und am 11. März um 10:00 Uhr ET auf der Barclays 27. jährlichen globalen Gesundheitskonferenz in Miami präsentieren.
Investoren und Interessierte können die Live-Audio-Webcasts und die Aufzeichnungen beider Präsentationen über den Bereich Investoren & Medien auf der Website von BioCryst unter biocryst.com abrufen.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
- TD Cowen 45th Annual Health Care Conference in Boston on Wednesday, March 5, 2025, at 9:10 a.m. ET.
- Barclays 27th Annual Global Healthcare Conference in Miami on Tuesday, March 11, 2025, at 10:00 a.m. ET.
Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
When is BioCryst (BCRX) presenting at the TD Cowen Healthcare Conference in 2025?
What time is BCRX presenting at the Barclays Healthcare Conference in March 2025?
How can investors access BioCryst's (BCRX) conference presentations in March 2025?
Which investor conferences is BCRX attending in March 2025?
